American Superconductor Is A House Of Cards Set To...
American Superconductor stock has risen over 100% since July 2018 on little progress in its businesses. We expect a fade...
Research
(If you're unable to access an article, contact us and we'll email you the full article)
Why Hospitals Are Not Buying T2 Biosystems Diagnostic System...
T2 Biosystems’ recent Breakthrough Device designation by the FDA isn’t an acknowledgement of the device’s effectiveness or clinical value proposition,...
Apyx Medical Is About To Have A Liposuction –...
Apyx is a provider of J-Plasma technology that has failed every medical application and is now only targeted for two...
New Age Beverages Is About To Take A Spill...
NBEV is a $500M market cap struggling US beverage roll-up attempting to reinvent itself by marketing CBD-infused drinks The Company’s...
FSD Pharma: A Rollup With Scattered, Uneconomical Cannabis Investments,...
FSD Pharma’s founder, Thomas Fairfull, and director, Anthony Durkacz, have a history of value destruction. Durkacz had an average loss...
Helius Medical: A Failed Clinical Trial, Redacted Data, And...
Helius Medical is a reverse-merger, single-product, pre-revenue medical device company with a unique device that delivers stimulation to the tongue...
Orchids Paper: Toliet Paper Never Looked So Dirty –...
Each 2018 quarter, Orchids Paper (TIS) has had a consecutively worse financial performance. For the past two quarters, Orchids' gross...
Transenterix: Surgical Robot Experts Call Its Senhance System ‘A...
TransEnterix (TRXC) was originally funded by a notorious investor recently charged by the SEC for orchestrating pump and dumps. A...
Namaste Technologies’ Major Related-Party Transactions Go Beyond Citron’s Findings
We found Namaste’s consultants are actually officers of the company, including the head of its audit committee. While other companies...
Generation Next Franchise Brands Is A House Made Of...
Generation Next Franchise Brands Is A House Made Of Frozen Yogurt That’s About To Melt Generation Next Franchise Brands’ (VEND)...
Viveve Medical Is A Sinking Ship, $0.90 Price Target
Viveve Medical (VIVE) had a horrendous Q1 2018 report with a big revenue miss, decreased gross margins, and a $12M...
Level Brands Is A Low Value Reg A+ IPO...
Level Brands (LEVB) is among the latest 2017 Reg A+ IPOs – so far they are all trading below their...
Track Record
We have an over 90% success rate
3rd Party Verified:
(click on the stock symbols below to see the reports)
Get Our Latest Reports Delivered To Your Inbox (we will not share your email with anyone)